Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedMay 28, 2026
DataAggregated Company Financials
Companies319
  • 7D3.6%
  • 3M0.1%
  • 1Y43.9%
  • YTD5.3%

The Pharma industry is up 2.6% in the last week, with Eli Lilly up 4.2%. Meanwhile, Regencell Bioscience Holdings actually underperformed within the industry, shrinking 13% in the last week. This means that the industry has gained 41% over the past year. Looking forward, earnings are forecast to grow by 14% annually.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 28 May 2026US$2.4tUS$424.1bUS$66.2b15.4x35.5x5.5x
Sat, 25 Apr 2026US$2.2tUS$408.1bUS$66.8b15.9x33.3x5.4x
Mon, 23 Mar 2026US$2.2tUS$406.1bUS$72.0b16.6x30.5x5.4x
Wed, 18 Feb 2026US$2.4tUS$411.5bUS$73.9b20.1x32.3x5.8x
Fri, 16 Jan 2026US$2.3tUS$402.6bUS$71.5b20.8x32.4x5.8x
Sun, 14 Dec 2025US$2.2tUS$402.7bUS$71.4b19.7x30.8x5.5x
Tue, 11 Nov 2025US$2.0tUS$396.3bUS$70.8b18.1x27.7x4.9x
Thu, 09 Oct 2025US$1.9tUS$387.6bUS$61.0b18.3x31.4x4.9x
Sat, 06 Sep 2025US$1.8tUS$387.9bUS$61.0b19x29.2x4.6x
Mon, 04 Aug 2025US$1.7tUS$382.0bUS$54.8b17.8x31.5x4.5x
Wed, 02 Jul 2025US$1.7tUS$382.7bUS$61.2b17.5x28x4.5x
Fri, 30 May 2025US$1.7tUS$382.6bUS$61.2b17.8x27x4.3x
Sun, 27 Apr 2025US$1.8tUS$379.6bUS$63.1b16.2x28.5x4.7x
Tue, 25 Mar 2025US$1.9tUS$381.1bUS$41.3b17x45.6x4.9x
Thu, 20 Feb 2025US$1.8tUS$381.0bUS$39.0b18.2x46.9x4.8x
Sat, 18 Jan 2025US$1.8tUS$369.3bUS$31.2b18.9x57.3x4.8x
Mon, 16 Dec 2024US$1.8tUS$373.8bUS$30.7b18.4x59.3x4.9x
Wed, 13 Nov 2024US$1.9tUS$373.6bUS$30.9b20.5x61.6x5.1x
Fri, 11 Oct 2024US$2.0tUS$364.2bUS$25.3b18.3x79.9x5.5x
Sun, 08 Sep 2024US$2.0tUS$364.1bUS$25.5b17.8x78.9x5.5x
Tue, 06 Aug 2024US$1.9tUS$359.3bUS$22.1b15.1x86.7x5.3x
Thu, 04 Jul 2024US$1.9tUS$357.6bUS$13.8b15x140.4x5.4x
Sat, 01 Jun 2024US$1.9tUS$358.3bUS$14.1b15.9x132.2x5.2x
Mon, 29 Apr 2024US$1.8tUS$359.5bUS$17.5b22.4x102.8x5x
Wed, 27 Mar 2024US$1.9tUS$355.3bUS$22.6b18.8x82.8x5.3x
Fri, 23 Feb 2024US$1.9tUS$355.0bUS$23.9b29x78.6x5.3x
Sun, 21 Jan 2024US$1.7tUS$375.2bUS$33.9b27.7x51.6x4.7x
Tue, 19 Dec 2023US$1.6tUS$375.1bUS$33.9b26.7x48.6x4.4x
Thu, 16 Nov 2023US$1.6tUS$375.5bUS$34.2b31.1x48x4.4x
Sat, 14 Oct 2023US$1.7tUS$381.8bUS$43.8b18.3x38.9x4.5x
Mon, 11 Sep 2023US$1.8tUS$381.8bUS$43.9b19.1x41.6x4.8x
Wed, 09 Aug 2023US$1.8tUS$381.3bUS$44.2b20.5x40.2x4.7x
Fri, 07 Jul 2023US$1.7tUS$392.8bUS$60.2b19.3x28.1x4.3x
Sun, 04 Jun 2023US$1.7tUS$393.0bUS$60.5b18.9x28.3x4.4x
Price to Earnings Ratio

28.3x


Total Market Cap: US$1.7tTotal Earnings: US$60.5bTotal Revenue: US$393.0bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 54x202420252026
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 35.8x which is lower than its 3-year average PE of 54.0x.
  • The 3-year average PS ratio of 5.0x is lower than the industry's current PS ratio of 5.6x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 3.1% per year over the last three years.
  • Revenues for these companies have grown 2.6% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.27%
Healthcare0.96%
Pharma3.56%
Pharma3.56%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LLY Eli LillyUS$1.08k6.3%
+US$57.1b		50.5%PE38.2x
MRK MerckUS$120.246.4%
+US$17.9b		57.9%PE33.2x
JNJ Johnson & JohnsonUS$231.290.9%
+US$4.7b		51.7%PE26.5x
PFE PfizerUS$26.211.6%
+US$2.4b		13.1%PE20x
ELAN Elanco Animal HealthUS$23.6913.6%
+US$1.4b		76.8%PS2.4x

Latest News

ZTS
US$79.48
Zoetis
7D
-0.3%
1Y
-51.9%
LLY
US$1,082.92
Eli Lilly
7D
6.3%
1Y
50.5%
Seeking Alpha • 2h

Eli Lilly: Big Upside Likely (Rating Upgrade)

Summary Eli Lilly is up by 12% since I last checked in April, but this is far from the potential upside for the stock right now. The company's latest results and upgraded guidance indicate at least 30-50% price upside, even considering the costs of its two latest acquisitions. There could be small corrections if the company continues to make more acquisitions, given Foundayo's slow ramp-up, but the bigger picture is overwhelmingly positive right now. Read the full article on Seeking Alpha
CORT
US$66.65
Corcept Therapeutics
7D
12.9%
1Y
-14.2%
JNJ
US$231.29
Johnson & Johnson
7D
0.9%
1Y
51.7%
MRK
US$120.24
Merck
7D
6.4%
1Y
57.9%
RPRX
US$53.97
Royalty Pharma
7D
1.7%
1Y
65.4%
BMY
US$57.52
Bristol-Myers Squibb
7D
-1.7%
1Y
22.5%
Seeking Alpha • 18h

Bristol-Myers Squibb Is Quietly Building Its Next Growth Cycle

Summary Bristol-Myers Squibb Company sees its business tracking toward the upper end of full-year 2026 revenue and EPS guidance ranges. In my view, this primarily reflects strong demand for Breyanzi, Camzyos, and Reblozyl. Sales of this "trio" were $1.28 billion in Q1, up 42.2% year-over-year. Also, this Friday at ASCO 2026, Bristol-Myers Squibb will begin presenting full data on its experimental "gems," including izalontamab brengitecan and pumitamig. In this article, I presented 4 more factors explaining why its risk/reward profile remains attractive to income-oriented investors. Read the full article on Seeking Alpha
SUPN
US$46.64
Supernus Pharmaceuticals
7D
-4.2%
1Y
45.1%
Narrative Update • May 26

SUPN: Resolved Supply Constraints Will Support Forward Repricing Case

Analysts have raised their price target on Supernus Pharmaceuticals stock to $65 from $60, citing updated models after Q4 results and increased confidence that Onapgo supply constraints are easing as additional production capacity comes online. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$65 price target as reflecting updated Q4 assumptions and a clearer picture of the company’s earnings power.
TARS
US$60.06
Tarsus Pharmaceuticals
7D
-7.3%
1Y
42.8%
Narrative Update • May 26

TARS: Lyme Disease Prevention Program Will Support Future Upside Potential

Analysts have adjusted their price target on Tarsus Pharmaceuticals to $100, reflecting updated views on its revenue outlook, profit margins and future P/E assumptions. What's in the News Tarsus dosed the first participant in the Phase 2 Calliope trial of TP-05, an oral therapy designed to potentially prevent Lyme disease by killing infected ticks before transmission, with plans to enroll about 700 healthy adults across Lyme-endemic regions in the U.S. (company announcement) The Calliope trial is randomized, double blind and placebo controlled, and is designed to assess safety, tolerability and pharmacokinetics of TP-05 in adults at risk for Lyme disease, where there are currently no FDA approved pharmacological prophylactic options.
PFE
US$26.21
Pfizer
7D
1.6%
1Y
13.1%
Narrative Update • May 25

PFE: Obesity And Oncology Pipeline Progress Will Drive Long-Term Upside Potential

Analysts have nudged Pfizer's implied fair value slightly higher to about $29.19 per share, reflecting a series of mostly modest price target increases, including Wolfe Research's move to $26. This comes alongside updated views on long term sales, COVID uncertainty, patent settlements around Vyndamax, and the recent Veppanu licensing, as well as GLP-1 and oncology pipeline commentary.
VTRS
US$16.29
Viatris
7D
-1.8%
1Y
89.6%
RGC
US$23.71
Regencell Bioscience Holdings
7D
-12.2%
1Y
21.6%
NKTR
US$65.40
Nektar Therapeutics
7D
-5.9%
1Y
523.5%
MANE
US$100.13
Veradermics
7D
-4.9%
1Y
n/a
LGND
US$235.89
Ligand Pharmaceuticals
7D
8.3%
1Y
135.4%
ELAN
US$23.69
Elanco Animal Health
7D
13.6%
1Y
76.8%